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Abstract
Purpose of the Review Breast lesions of uncertain malignant potential (B3) are a heterogeneous group of diagnostic entities that
can be associated with atypia. These are associated with in situ or invasive malignancy in 20–30% of cases. The management of
those lesions has been both controversial and challenging for the multidisciplinary teams.
Recent Findings This is an up-to-date review of the current International Consensus on the management of B3 lesions with
emphasis on the practical considerations.
Summary Through multidisciplinary management pathways, the vast majority of B3 lesions should be managed by vacuum-
assisted excision, rather than surgical excision. Exceptions to this pathway and the rationale for surgical excision are discussed.
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Abbreviations
ADH Atypical ductal hyperplasia
AIDEP Atypical intraductal epithelial proliferation
ALH Atypical lobular hyperplasia
ASBS The American Society of Breast Surgeons
DCIS Ductal carcinoma in situ
FEA Flat epithelial atypia
LCIS Lobular carcinoma in situ
NBSS National Breast Screening System




The UK breast screening programme classifies a group of
breast lesions of uncertain malignant potential as B3 lesions.
This is a heterogeneous category encompassing a number of
lesions that may or may not be associated with cytological
and/or architectural atypia.
The B3 category includes cellular fibroepithelial lesions
(where phyllodes tumour is considered), flat epithelial atypia
(FEA), lobular in situ neoplasia (including ALH, LCIS), atyp-
ical intraductal epithelial proliferation (AIEDP), intraduct
papillomas (with and without atypia), radial scars (with and
without atypia) and mucocele-like lesions. A combination of
the B3 lesions is known to occur particularly in the spectrum
of low nuclear grade neoplasia family (FEA, lobular neopla-
sia, AIDEP) [1]. Other less common lesions within this cate-
gory include apocrine atypia, myofibroblastomas, vascular le-
sions and bland spindle cell lesions.
The proportion of B3 lesions varies across institutions
both nationally and internationally. In the UK, the report-
ed rate between 1999 and 2006 was 5% (range
2.417.93%) [2]. In large European series, the B3 rate
was reported at 4.5% in Germany [3], 11.9% in Italy [4]
and 17% in Switzerland [5]. A recent study of 5750 nee-
dle core biopsies in the USA showed an incidence of 8%,
of which atypical ductal hyperplasia (ADH) was the
commonest lesion (4.3%) [6].
Histologically, some of the B3 entities, such as FEA and
AIDEP (Fig. 1a, b), are known to be diagnostically challeng-
ing with significant inter and intra observer variation [7]. The
reproducibility of diagnosis however is higher among special-
ist breast pathologists and improves on applying agreed
criteria for diagnosis [8].
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B3 Upgrade Rate
Many studies assessed the upgrade rate to in situ or invasive
carcinoma (positive predictive value) following the diagnosis
of B3. Overall, the association with malignancy is seen in 20–
30% of cases [2, 3, 9•], Table 1. Most of the upgrades are to in
situ rather than invasive carcinoma. In other words, the ma-
jority of B3 lesions show a final benign diagnosis.
It has long been known that the rate of progression to ma-
lignancy is low and occurs over a long period [14]. The can-
cers that develop in a small proportion of B3 lesions are often
of the low-grade hormone receptor–positive type (i.e. good
prognosis group). The rationale for further sampling, howev-
er, is to exclude coexistent, more advanced disease that could
have been missed by the diagnostic core biopsy. The B3 le-
sions can be heterogeneous co-existing with in situ or invasive
carcinoma in only part of the lesion hence the need for further
tissue examination. This ensures adequate sampling to ex-
clude associated focal carcinoma. Therefore, vacuum-
assisted excision is considered a viable alternative to surgical
diagnostic excision as treatment option.
Current Guidelines for Management of B3
Lesions
The management of those lesions has been challenging.
Traditionally, B3 lesions are managed by surgical excision.
There has been a trend globally to use VAE for the manage-
ment of B3 lesions with no atypia, such as radial scars and
papillomas with no atypia [15]. The B3 lesions with atypia
are, however, still managed with diagnostic surgical excision
in Europe and the USA.
The first International Consensus Conference on lesions of
uncertain malignant potential in the breast recommended VAE
as the gold standard for managing the majority of those lesions
[16]. The recently published second International Consensus
endorsed those recommendations [17••]. Similarly, the UK
published imaging guidance [18], followed by detailed path-
ological guidelines [19••] on the diagnostic criteria, signifi-
cance and management of each B3 category. The UK guide-
lines recommend vacuum-assisted excision (VAE) as the gold
standard for managing all B3 lesions, except papilloma with
atypia, spindle cell lesions and fibroepithelial lesions.
Fig. 1 Histological features of flat epithelial atypia, atypical intraductal
epithelial proliferation and marker clip reactions. a Flat epithelial atypia
(FEA) with luminal calcifications. There is a dilated terminal duct lobular
unit lined by slightly enlarged hyperchromatic cells showing low-grade
cytological atypia. The ductal lumina show secretion and round
calcification. Note the absence of high-grade cytological atypia. b
Atypical intraductal epithelial proliferation (AIDEP). This breast core
shows two ducts with architectural atypia showing a cribriform pattern.
The intraductal proliferation is incompletely involved by low-grade
atypical cells and the lesional size is less than 2 mm and therefore does
not amount to ductal carcinoma in situ. c An example of marker clip
reaction. The bottom of the figure shows the architecture of a marker
clip comprising interconnecting trabecula of acellular eosinophilic
material. This is surrounded by a florid foreign body giant cell reaction
and chronic inflammation. dA different type of marker clips in VAE core
comprising a cystic space lined by histiocytes and foreign body giant
cells. The adjacent breast tissue shows fat necrosis consistent with
previous sampling
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The rationale for opting for a diagnostic excision following
the diagnosis of papillary lesion with atypia is to allow pathol-
ogists to measure the precise extent of atypia to differentiate
between atypia within a papilloma (ADH, < 3 mm) and DCIS
within a papilloma (> 3 mm). The diagnosis of phyllodes tu-
mour and its categorisation into benign/borderline/malignant
requires the assessment of several histological criteria includ-
ing the status of the margin (circumscribed vs infiltrative) and
adequacy of excision.
It is to be noted that there are some discrepancies between
the European and UK recommendations for managing B3
lesions. For example, the International Consensus recom-
mends a surgical excision following an AIDEP diagnosis
[17••]. On the other hand, lobular neoplasia on core biopsy
without discordant imaging is often managed by imaging
follow-up in the USA [20] and this is supported by the
National Comprehensive Cancer Network (NCCN) and the
American Society of Breast Surgeons (ASBS) guidelines
[21••].
Diagnostic Vacuum–Assisted Biopsy vs
Vacuum-Assisted Excision
It is important to clarify the use of terminology in relation to
the vacuum biopsy device. Vacuum-assisted biopsy (VAB) is
where the conventional 14G needle has been replaced with a
vacuum biopsy needle (usually 12-9G) and the aim is to ob-
tain a diagnosis. VAB allows sampling a larger amount of
tissue (compared with conventional needle core biopsy) to
provide enough tissue for the pathologists to make a diagno-
sis. The purpose is not to excise the whole lesion. Similar to
conventional core biopsy, a final B-category is recorded.
Vacuum-assisted excision (VAE) is used to replace surgical
diagnostic biopsy. Often, 7 or 8G needle is used and the aim is
to obtain plentiful samples to equate to a surgical biopsy with
representative sampling. The aim is to take about 4G of tissue
which is often estimated by multiplying the number of cores
with estimated weight of each core dependent on the needle
size [19••]. The advent of vacuum technology has the advan-
tage of adequate tissue sampling without the complications of
surgical excision. Small lesions, typically less than 15 mm,
may be completely excised by VAE.
Advantages of VAE
There have been concerns regarding the over diagnosis
and overtreatment of women within the breast screening
programme. Women with a likely outcome of a benign
diagnosis should not therefore be exposed to unneces-
sary surgery.
VAE is a well-tolerated outpatient procedure aiming to
sample further tissue to exclude more advanced lesions.
Considering that the majority of B3 patients end up with a
final benign diagnosis, the technique saves those patients un-
necessary surgical excisions. Patients can therefore avoid the
unwanted complications of surgery including anaesthetic
complications, scarring and difficult follow-up mammograph-
ic surveillance due to post-surgical changes.
The prevalent benign operative biopsy rate within the UK
has been variable. The minimum standard is 1.5 per 100,000
and target is 1 per 100,000. The outlier units are generally
those who have not implemented this pathway. VAE reduces
the benign diagnostic biopsy rate and improves the preopera-
tive diagnostic rate without affecting the cancer detection rate.
Table 1 Summary of recent international studies on upgrade rate of B3 lesions to in situ and/or invasive carcinoma











Elsayed et al. 2008 [2] UK East Midlands
region




Strachan et al. 2008 [9•] UK single institution 2009–2013 4 Not stated 398 40 20
Bianchi et al. 2011 [4] Multi institutional
Italian series
1998–2009 11 26,165 3107 (11.9%) 349 (out of 1644
excised)
21.2
Nguyen et al. 2011 [10] US single institution
(MDAnderson centre)
1997–2009 12 5383 433 ADH (9.9) 16 13.2
Rakha et al. 2011 [11] UK single Institution 2007–2008 2 3347 149 (4.5) 15 10
Renshaw and Gould 2016 [12] US single institution 2000–2004 4 Not stated 244 including
175 ADH
and 69 LCIS
53 for ADH and
3 for LCIS
34.6
Mooney et al. 2016 [6] US single institution 2003–2014 14.5 5750 462(8) 56 (out of 333
excised)
17
Mayer et al. 2017 [13] German single institution 2009–2013 4 Not stated 219 22 10
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Marker Clips
The insertion of a marker clip is strongly recommended in the
sampling of calcification. If more than one area is being sam-
pled, it is good practice to use a different clip type per area.
This will allow accurate identification of the sampled areas
particularly if the histological diagnoses are different.
Pathological correlation including identifying the marker clip
reaction histologically is important to ascertain sampling of
the area of interest. The histological appearances of the marker
clips vary with the type inserted and these are often associated
with a florid inflammatory and foreign body giant cell reaction
(Fig. 1c, d).
Recording of Breast Screening Data
Currently, a B coding is provided for all core biopsy diagno-
ses. VAE is a larger biopsy that is meant to replace diagnostic
excision and hence a final B coding is not required. The cur-
rent National Breast Screening System (NBSS) has been
adapted so that this data can now be collected from all the
breast screening units providing national data on how B3 le-
sions are being managed. All the fields related to a B3 diag-
nosis are now mandatory where the type of B3 lesion is re-
corded and the presence or absence of atypia noted. The VAE
is also recorded on NBSS as a mandatory field. No final B
coding is required by pathologists or recorded for those le-
sions excised by vacuum biopsy [22••]. The NHS Breast
Screening Programme are keen to minimise overtreatment in
the context of B3 lesions and have created a new KPI (key
performance indicator) where all appropriate B3 lesions
should be managed with VAE and < 25% of B3 lesions should
be managed with surgery.
All 80 screening units within the UK will be audited on a
yearly basis and units where the surgical diagnostic biopsy
rate is > 25%, the units will have to audit their practice and
explain why they have not achieved the target.
Follow-up Following a B3 Diagnosis
One important issue following the diagnosis of B3 lesions,
particularly those with atypia, is whether to follow patients
up radiologically and the length and frequency of follow-up.
There is no hard evidence to guide the duration and frequency
of follow-up. The International Consensus paper recommend-
ed surveillance following a B3 diagnosis including for non-
atypical lesions (papilloma, radial scars) and more frequent
surveillance for lobular neoplasia [17••].
The current UK guidelines recommend annual mam-
mographic follow-up for 5 years followed by return to
the 3 yearly routine breast cancer screening. This will




Histologically, the term ‘AIDEP’ is recommended for de-
scribing low-grade atypical ductal hyperplasia (ADH) di-
agnosed on core biopsy and/or diagnostic VAB. The
‘ADH’ terminology is quantitative and can only be used
when the area of interest has been thoroughly sampled
and the extent of the lesion confirmed to be less than
2 mm [19••]. Lesions larger than 2 mm are designated
as ductal carcinoma in situ (DCIS).
Reporting of Atypia
It is recommended that the diagnosis of B3 lesions should
include a comment on the presence/absence of atypia.
Atypia is associated with a higher risk of upgrade to in
situ/invasive carcinoma among all B3 lesions [9•, 13, 23].
The presence of atypia can also alter the management plans.
For example; benign papillomas without atypia are managed
by VAE whereas those with atypia require diagnostic surgical
excisions [19••].
Complete Excision of Lesion
For some B3 lesions, complete excision of the lesion may
be done on the first diagnostic VAB and no further abnor-
mality can be identified on VAE examination. This is not
uncommon. It is important in this context to confirm that
the correct area has been sampled (histological evidence
of previous core/VAB biopsy site and/or marker clip
reaction).
Adequacy of Excision
Due to the piecemeal nature of the vacuum biopsies, it is not
possible for pathologists to comment on the adequacy of ex-
cision (e.g. for a radial scar, papilloma). Decisions on ade-
quate excision in those instances will depend on the radiolog-
ical impression.
Clip Migration
In a small proportion of cases, haematoma leading to clip
migration may occur. In those instances, radiological review
and documentation is required.
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Radiological Pathological Discordance
Radiological pathological correlation is the essence on the B3
management pathway. For discordant lesions (e.g. histological
findings do not explain a mass lesion or calcification not iden-
tified), a repeat VAB and/or a diagnostic excision may be
required. Discussion at the multidisciplinary meeting with
careful planning and documentation are therefore important.
Conclusions
The current B3 management pathway is multidisciplinary and
recommends the use of VAE as the standard for the majority of
B3 lesions. This pathway ensures adequate sampling to ex-
clude coexistent in situ or invasive carcinoma. Yearly mam-
mographic surveillance for 5 years is also recommended for
atypical lesions. A separate category for VAE coding on
NBSS is now available. Regular auditing and collection of
outcome data will allow refining recommendations on the
duration and frequency of follow-up.
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